KLK3 and neoplasm: The IMPACT Trial demonstrated a median overall survival benefit of approximately 4.1 months compared to the placebo (25.8 vs. 21.7 months), but little or no impact on measurable disease progression, PSA declines, or objective tumor shrinkage [122].